1
|
Lv Y, Zhao H, Liu S, Meng Y, Yu W, Liu T, Sun Q, Shen M, Ren X, Liu L. Anlotinib and anti-PD-1 mAbs perfected CIK cell therapy for lung adenocarcinoma in preclinical trials. J Leukoc Biol 2024; 116:544-554. [PMID: 38373017 DOI: 10.1093/jleuko/qiae037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2023] [Revised: 12/30/2023] [Accepted: 01/25/2024] [Indexed: 02/20/2024] Open
Abstract
Murine cytokine-induced killer (CIK) cells are heterologous cells that kill various allogeneic and isogenic tumors and have functional and phenotypic characteristics of natural killer cells and T lymphocytes. However, the effect of CIK cells alone on solid tumor therapy is only limited. To enhance the therapeutic effect, it is vital to discover a mix of several therapy approaches. Immune cell function is inhibited by abnormal tumor vessels and the tumor microenvironment, which block lymphocyte entry into tumor tissue. To increase the effectiveness of CIK cells' antitumor activity, antivascular therapy and CIK cell therapy can be combined. Furthermore, anlotinib is a tiny drug with multitarget tyrosine kinase inhibitors that can block cell migration, delay angiogenesis, and decrease blood vessel density. Compared with other antiangiogenesis drugs, anlotinib stands out due to the wider target of action and lower effective dose. In this work, anlotinib and murine CIK cells were coupled to boost CD3+ T cell infiltration, CD3+CD4+ T cell infiltration, and expression of granzyme B and interferon γ from CD3+CD8+ T cells, which increased the antitumor activity. Through the generation of cytotoxic cytokines by T lymphocytes, the therapeutic group using anti-PD-1 monoclonal antibodies in conjunction with anlotinib and CIK cells was more successful than the group receiving dual therapy. The preclinical study contributes to exploring the therapeutic alternatives for patients with lung adenocarcinoma, thus prolonging their lives.
Collapse
Affiliation(s)
- Yingge Lv
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
| | - Hua Zhao
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Haihe Laboratory of Cell Ecosystem, Yuexin Road, Binhai New District, Tianjin, 300060, China
| | - Shaochuan Liu
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
| | - Yuan Meng
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
| | - Wenwen Yu
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
| | - Ting Liu
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
| | - Qian Sun
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Haihe Laboratory of Cell Ecosystem, Yuexin Road, Binhai New District, Tianjin, 300060, China
| | - Meng Shen
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
| | - Xiubao Ren
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Haihe Laboratory of Cell Ecosystem, Yuexin Road, Binhai New District, Tianjin, 300060, China
| | - Liang Liu
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Prevention and Therapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Tianjin's Clinical Research Center for Cancer, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Key Laboratory of Cancer Immunology and Biotherapy, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
- Department of Biotherapy, Tianjin Medical University Cancer Institute and Hospital, Huanhu Xi Road, Hexi District, Tianjin, 300060, China
| |
Collapse
|
2
|
Ribeiro AB, de Melo MRS, de Melo Junqueira M, Rodrigues MGL, de Souza TO, Fernandes G, Santos MFC, Ambrósio SR, Bastos JK, Tavares DC. Efficacy and safety of guttiferone E in melanoma-bearing mice. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 2024; 397:5265-5274. [PMID: 38270618 DOI: 10.1007/s00210-024-02962-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2023] [Accepted: 01/15/2024] [Indexed: 01/26/2024]
Abstract
Melanoma, an aggressive and potentially fatal skin cancer, is constrained by immunosuppression, resistance, and high toxicity in its treatment. Consequently, there is an urgent need for innovative antineoplastic agents. Therefore, this study investigated the antimelanoma potential of guttiferone E (GE). In an allogeneic murine B16 melanoma model, GE was administered subcutaneously and intraperitoneally. Antitumor evaluation included tumor volume/weight measurements and histopathological and immunohistochemical analysis. Furthermore, the toxicity of the treatments was evaluated through body/organ weights, biochemical parameters, and genotoxicity. Subcutaneous administration of 20 mg/kg of GE resulted in a significant reduction in both tumor volume and weight, effectively suppressing melanoma cell proliferation as evidenced by a decrease in mitotic figures. The tumor growth inhibition rate was equivalent to 54%. This treatment upregulated cleaved caspase-3, indicating apoptosis induction. On the other hand, intraperitoneal administration of GE showed no antimelanoma effect. Remarkably, GE treatments exhibited no toxicity, evidenced by non-significant differences in body weight gain, as well as organ weight, biochemical parameters of nephrotoxicity and hepatotoxicity, and genotoxic damage. This study revealed, for the first time, the efficacy of subcutaneous administration of GE in reducing melanoma, in the absence of toxicity. Furthermore, it was observed that the apoptotic signaling pathway is involved in the antimelanoma property of GE. These findings offer valuable insights for further exploring GE's therapeutic applications in melanoma treatment.
Collapse
Affiliation(s)
- Arthur Barcelos Ribeiro
- University of Franca, Avenida Dr. Armando Salles Oliveira, 201, Parque Universitário, Franca, São Paulo, 14404-600, Brazil.
| | - Matheus Reis Santos de Melo
- University of Franca, Avenida Dr. Armando Salles Oliveira, 201, Parque Universitário, Franca, São Paulo, 14404-600, Brazil
| | - Marcela de Melo Junqueira
- University of Franca, Avenida Dr. Armando Salles Oliveira, 201, Parque Universitário, Franca, São Paulo, 14404-600, Brazil
| | - Mônica Garcia Leal Rodrigues
- University of Franca, Avenida Dr. Armando Salles Oliveira, 201, Parque Universitário, Franca, São Paulo, 14404-600, Brazil
| | - Thiago Olimpio de Souza
- University of Franca, Avenida Dr. Armando Salles Oliveira, 201, Parque Universitário, Franca, São Paulo, 14404-600, Brazil
| | - Gabriela Fernandes
- University of Franca, Avenida Dr. Armando Salles Oliveira, 201, Parque Universitário, Franca, São Paulo, 14404-600, Brazil
| | | | - Sérgio Ricardo Ambrósio
- University of Franca, Avenida Dr. Armando Salles Oliveira, 201, Parque Universitário, Franca, São Paulo, 14404-600, Brazil
| | - Jairo Kenupp Bastos
- School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Av. do Café s/n, Ribeirão Preto, São Paulo, 14040-903, Brazil
| | - Denise Crispim Tavares
- University of Franca, Avenida Dr. Armando Salles Oliveira, 201, Parque Universitário, Franca, São Paulo, 14404-600, Brazil.
| |
Collapse
|
3
|
Hurtado-Díaz I, Ramírez-Cisneros MÁ, Alvarez L, Sánchez-Carranza JN, Columba-Palomares MC, Silva-Guzmán JA, Cruz-Sosa F, Bernabé-Antonio A. Metabolites Profile of Extracts and Fractions of Erythroxylum mexicanum Kunth by UHPLC-QTOF-MS/MS and its Antibacterial, Cytotoxic and Nitric Oxide Inhibitory Activities. Chem Biodivers 2024; 21:e202301474. [PMID: 38215210 DOI: 10.1002/cbdv.202301474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Revised: 01/08/2024] [Accepted: 01/12/2024] [Indexed: 01/14/2024]
Abstract
The present study shows the untargeted metabolite profiling and in vitro antibacterial, cytotoxic, and nitric oxide (NO) inhibitory activities of the methanolic leaves extract (MLE) and methanolic stem extract (MSE) of Erythroxylum mexicanum, as well as the fractions from MSE. Using ultra-high performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry (UHPLC-QTOF-MS/MS), a total of 70 metabolites were identified; mainly alkaloids in the MLE, while the MSE showed a high abundance of diterpenoids. The MSE fractions exhibited differential activity against Gram-positive bacteria. Notably, the hexane fraction (HSF) against Streptococcus pyogenes ATCC 19615 (MIC=62.5 μg/mL) exhibited a bactericidal effect. The MSE fractions exhibited cytotoxicity against all cancer cell lines tested, with selectivity towards them compared to a noncancerous cell line. Particularly, the HSF and chloroform fraction (CSF) showed the highest cytotoxicity against prostate cancer (PC-3) cells, with IC50 values of 19.9 and 18.1 μg/mL and selectivity indexes of 3.8 and 4.2, respectively. Both the HSF and ethyl acetate (EASF) fractions of the MSE inhibited NO production in RAW 264.7 macrophages, with NO production percentages of 50.0 % and 51.7 %, respectively, at a concentration of 30 μg/mL. These results indicated that E. mexicanum can be a source of antibacterial, cytotoxic, and anti-inflammatory metabolites.
Collapse
Affiliation(s)
- Israel Hurtado-Díaz
- Department of Wood, Pulp and Paper, University Center of Exact Sciences and Engineering, University of Guadalajara, Km 15.5 Guadalajara-Nogales, Col. Las Agujas, 45200, Zapopan, Jalisco, Mexico
| | - M Ángeles Ramírez-Cisneros
- Chemical Research Center-IICBA, Autonomous University of the State of Morelos, Av. Universidad 1001, Chamilpa, 62209, Cuernavaca, Morelos, Mexico
| | - Laura Alvarez
- Chemical Research Center-IICBA, Autonomous University of the State of Morelos, Av. Universidad 1001, Chamilpa, 62209, Cuernavaca, Morelos, Mexico
| | - Jessica Nayelli Sánchez-Carranza
- Faculty of Pharmacy, Autonomous University of the State of Morelos, Av. Universidad 1001, Chamilpa, 62209, Cuernavaca, Morelos, México
| | - María Crystal Columba-Palomares
- Faculty of Pharmacy, Autonomous University of the State of Morelos, Av. Universidad 1001, Chamilpa, 62209, Cuernavaca, Morelos, México
| | - José Antonio Silva-Guzmán
- Department of Wood, Pulp and Paper, University Center of Exact Sciences and Engineering, University of Guadalajara, Km 15.5 Guadalajara-Nogales, Col. Las Agujas, 45200, Zapopan, Jalisco, Mexico
| | - Francisco Cruz-Sosa
- Department of Biotechnology, Autonomous Metropolitan University-Iztapalapa Campus, Av. Ferrocarril de San Rafael Atlixco 186, Col. Leyes de Reforma 1a. Sección, Alcaldía Iztapalapa, Mexico City, 09310, Mexico
| | - Antonio Bernabé-Antonio
- Department of Wood, Pulp and Paper, University Center of Exact Sciences and Engineering, University of Guadalajara, Km 15.5 Guadalajara-Nogales, Col. Las Agujas, 45200, Zapopan, Jalisco, Mexico
| |
Collapse
|